- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07720102
Patient Reported Outcomes Following Percutaneous Lung Ablation
July 17, 2026 updated by: Mayo Clinic
This study evaluates satisfaction with percutaneous ablation and any symptoms experienced before and after the procedure in patients with lung tumors.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
Principal Investigator:
- Ahmad Parvinian, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adult patients undergoing percutaneous lung ablation recruited from Mayo Clinic in Rochester
Description
Inclusion Criteria:
- Undergoing percutaneous lung ablation
Exclusion Criteria:
- Decline to participate in research
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Observational
Patients complete surveys throughout the study.
|
Non-interventional study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptom severity following percutaneous lung ablation
Time Frame: Baseline (prior to ablation), 1 day, 3 days, 7 days, 1 month, 3 months
|
Assessed using a study-specific survey.
Participants evaluate 5 symptoms (pain, fatigue, drowsiness, shortness of breath, and disturbed sleep), each on an 11-point Likert scale of 0-10 where 0=absence of symptoms and 10=as bas as you can imagine.
Higher scores indicate greater severity of symptoms.
|
Baseline (prior to ablation), 1 day, 3 days, 7 days, 1 month, 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ahmad Parvinian, MD, Mayo Clinic in Rochester
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
July 31, 2028
Study Completion (Estimated)
December 31, 2028
Study Registration Dates
First Submitted
July 17, 2026
First Submitted That Met QC Criteria
July 17, 2026
First Posted (Actual)
July 22, 2026
Study Record Updates
Last Update Posted (Actual)
July 22, 2026
Last Update Submitted That Met QC Criteria
July 17, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 26-000294
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Neoplasm
-
National Cancer Institute (NCI)RecruitingLocally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditionsUnited States
-
Dartmouth-Hitchcock Medical CenterCompletedPrimary Malignant Neoplasm of Lung | Primary Malignant Neoplasm of Gastrointestinal TractUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung Carcinoma | Lung Neoplasm | Malignant Lung NeoplasmUnited States
-
Bavarian Cancer RegistryBavarian Association of Statutory Health Insurance Accredited PhysiciansRecruitingNeuroendocrine Neoplasm of Lung | Neuroendocrine Neoplasm of Gastrointestinal Tract (Disorder)Germany
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
Jiangsu ShengDiYa Medicine Co., Ltd.Dongguan People's HospitalUnknownNonsquamous Nonsmall Cell Neoplasm of Lung
-
Spanish Lung Cancer GroupCompletedNonsquamous Nonsmall Cell Neoplasm of LungSpain
-
Rgene CorporationAmerican BriVision CorporationNot yet recruitingNonsquamous Nonsmall Cell Neoplasm of LungTaiwan
-
OncoMed Pharmaceuticals, Inc.Celgene CorporationCompletedNonsquamous Nonsmall Cell Neoplasm of LungSpain, United States, Australia, Italy, Belgium
Clinical Trials on Non-Interventional Study
-
City of Hope Medical CenterNot yet recruitingMalignant Solid Neoplasm | Hematopoietic Neoplasm | Hematopoietic and Lymphatic System Neoplasm | Lymphatic System Neoplasm
-
Ohio State University Comprehensive Cancer CenterCompletedHeavy Metal Exposure From VapingUnited States
-
Portsmouth Hospitals NHS TrustArdia Digital Health LtdRecruitingChronic Kidney DiseaseUnited Kingdom
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingProstate CarcinomaUnited States
-
Mayo ClinicRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterLilly FoundationRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Advanced Breast Carcinoma | Metastatic Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Enrolling by invitationBarrett Esophagus | Esophageal AdenocarcinomaUnited States
-
National Cancer Institute (NCI)Not yet recruitingHuman Papillomavirus-Related Malignant NeoplasmCosta Rica
-
Mayo ClinicRecruitingEndometrial CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterNational Institute on Aging (NIA)Not yet recruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Esophageal Adenocarcinoma AJCC v8 | Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Esophageal... and other conditionsUnited States